-FIERCE-21 and FIERCE-22 Phase 2 Trials in Metastatic Bladder Cancer-
SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately-held clinical stage drug
development company, today announced that abstracts related to trials of
the company’s lead therapeutic, vofatamab, have been accepted for
presentation at the upcoming 2019 American Society for Clinical Oncology
(ASCO) Annual Meeting, which will take place May 31 to June 4, 2019 in
Chicago, Illinois.
“We are pleased to have abstracts related to our ongoing Phase 2
vofatamab trials accepted for a poster discussion and poster
presentations at ASCO,” said Scott Myers, Chairman and CEO of Rainier
Therapeutics. “This includes a preliminary analysis of clinical activity
in FIERCE-22 and an interim analysis in FIERCE-21.”
Poster Discussion & Poster Presentation:
FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective
inhibitor in combination with pembrolizumab (P) in WT metastatic
urothelial carcinoma, preliminary analysis.
Abstract: 4511
Poster Discussion Session: Genitourinary (Nonprostate) Cancer
Date/Time:
Monday, June 3, 2019, 4:30 PM – 6:00 PM,
Location: Hall D2
Poster Session: Genitourinary (Nonprostate) Cancer
Poster
Board: #337
Date/Time: Monday, June 3, 2019, 1:15 PM – 4:15 PM,
Location:
Hall A
Presenter: Arlene O. Siefker-Radtke, MD, The University of Texas MD
Anderson Cancer Center
Poster Presentation:
Interim analysis of the FIERCE-21 phase 2 (P2) study of vofatamab
(B-701), a selective inhibitor of FGFR3, as salvage therapy in
metastatic urothelial carcinoma (mUC).
Abstract: 4547
Poster Session: Genitourinary (Nonprostate) Cancer
Poster Board:
#373
Date/Time: Monday, June 3, 2019, 1:15 PM – 4:15 PM
Location:
Hall A
Presenter: Begona Mellado, MD, PhD, Hospital Clinic de Barcelona
About Vofatamab
Vofatamab (formerly B-701) is an antibody specifically targeted against
the fibroblast growth factor receptor 3 (FGFR3), a known driver of
bladder and potentially other FGFR-driven cancers. Vofatamab is the most
advanced targeted antibody specific for FGFR3 known by Rainier
Therapeutics to be in clinical development. Vofatamab is currently being
evaluated in two clinical trials: FIERCE-21 and FIERCE-22.
FIERCE-21 is a Phase 2 trial evaluating vofatamab in combination with
docetaxel and separately vofatamab as monotherapy in patients with
locally advanced or metastatic bladder cancer with FGFR3
mutation/fusions who have relapsed after, or are refractory to, at least
one prior line of chemotherapy.
FIERCE-22 is a Phase 2 trial evaluating vofatamab in combination with
pembrolizumab, an immune checkpoint inhibitor, to determine safety,
tolerability and efficacy in the treatment of patients with locally
advanced or metastatic bladder cancer, who have progressed following
platinum-based chemotherapy and who have not received prior immune
checkpoint inhibitor therapy.
For additional information on FIERCE-21, please visit www.clinicaltrials.gov
(NCT02401542) and for more information on FIERCE-22, please visit www.clinicaltrials.gov
(NCT03123055).
Rainier Therapeutics also plans to study vofatamab in non-muscle
invasive bladder cancer (NMIBC) – the FIERCE-23 trial.
About Rainier Therapeutics
Rainier Therapeutics, Inc. is a privately-held, clinical stage
biotechnology company developing a targeted biologic for the potential
treatment of metastatic bladder cancer. The company’s antibody,
vofatamab (formerly B-701) is focused specifically on the fibroblast
growth factor receptor 3 (FGFR3), a known driver of bladder and other
cancers. For more information, please visit www.rainierrx.com.
Contacts
Julie Rathbun
Rathbun Communications
(206) 769-9291
julie@rathbuncomm.com